Dacarbazine for injection

1 Pharmacology: This product has anti-tumor effects. Since it is a precursor of purine biosynthesis, it can interfere with purine biosynthesis. After entering the body, it demethylates in the liver microsomes to form monomethyl compounds, which have direct cytotoxic effects. It mainly acts on the G2 phase. It inhibits the synthesis of purine, RNA and protein, and also affects the synthesis of DNA. Therefore, it is also considered to be an alkylating anti-tumor drug. 2 Toxicology: The experimental results show that the acute median lethal dose (LD50) of this product for mice injected intraperitoneally is 815mg/kgplusmn;50.9mg/kg.

Ingredients: Dacarbazine. Chemical name: 5-(3,3-dimethyl-1-triazene)-imidazole-4-carboxamide citrate.

This product is used to treat malignant melanoma

1. Intravenous injection. 200-400mg/m2 per day, for 5-10 days. To reduce irritation to blood vessels, use 10-15ml of normal saline, dissolve it, and then dilute it with 250ml of 5% glucose solution and drip it. It takes more than 30 minutes to drip it. 5-10 days of continuous use is a course of treatment. Generally, it is repeated every 3-6 weeks. For malignant melanoma of the limbs, arterial injection with a nutrient dose can be used. The blood concentration reaches a peak 30 minutes after each intravenous injection, drops to zero within 6 hours, and 30% is excreted in the urine within 0-6 hours. It cannot pass the blood-brain barrier. Single large dose: 650-1450mg/㎡, once every 4-6 weeks. 2. Intravenous drip: 200mg/㎡ each time, once a day, for 5 consecutive days, and repeated every 3-4 weeks. 3 Arterial perfusion: Arterial perfusion: Malignant melanoma located in the limbs can be treated with the same dose of arterial injection.

1. Gastrointestinal reactions: such as loss of appetite, nausea, vomiting, diarrhea, etc., which may be alleviated or disappear after 2 to 8 hours. 2. Bone marrow suppression: It may cause a decrease in white blood cells and platelets, and anemia, which is more obvious at high doses. Generally, a decrease in blood count occurs 2 to 3 weeks after medication, and it may return to normal in the 4th to 5th week. 3. A small number of patients may experience "flu"-like symptoms, such as general discomfort, fever, and muscle pain, which may occur 7 days after medication and last for 1 to 3 weeks. Facial numbness and hair loss may also occur. 4. Local reactions: There may be vascular irritation reactions at the injection site. 5. Occasionally, liver and kidney damage may occur.

1. Patients with chickenpox or herpes zoster are prohibited from using this product. 2. Patients with a history of severe allergies are prohibited from using this product. 3. Pregnant women are prohibited from using this product.

When this product is used in combination with other drugs or radiation that suppress the bone marrow, the dosage of this product should be reduced.

Store in a sealed container below 5°C and away from light.

0.1g (based on dacarbazine)

Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.

• Founded in:

  2012-07-20

• Address:

  Biomedical Park, No. 858 Gaoxin Avenue, Wuhan East Lake New Technology Development Zone (Wuhan Area of Free Trade Zone)

• Tax NO.:

  914201005979383918

• Registered Funds:

  230 million yuan

• Website:

  Log in to view

• Email:

  Log in to view